TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21722499
Drug: Abatacept approximately
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept approximately 10 mg/kg
Study: 19801244
Drug: Conventional irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irrigation with NaviTip needles (20 mL NaOCl and EDTA)
Study: 19801244
Drug: Conventional irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irrigation with NaviTip needles + EndoActivator (20 mL NaOCl and EDTA)
Study: 19801244
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with EndoVac system (43 mL NaOCl and EDTA)
Study: 19801244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with saline solution (43 mL)
Study: 10779265
Drug: High inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High inositol formula (2500 micromol/L)
Study: 10779265
Drug: Lower inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower inositol formula (710 and 242 micromol/L)
Study: 9313749
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (ultralente)
Study: 9313749
Drug: Sulfonylurea therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea therapy (gliclazide)
Study: 8376739
Drug: Serum vaccine
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum vaccine
Study: 8376739
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen (serum and recombinant vaccines)
Study: 8376739
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of serum-derived vaccine
Study: 28667207
Drug: Multidimensional intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidimensional intervention based on individual patient-reported outcomes (PROs) including electronic assessment of PRO, creation of a case vignette, and treatment suggestions from expert panel discussions.
Study: 28667207
Drug: Usual supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual supportive treatment.
Study: 21735983
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of soya and soya-based supplements
Study: 21283922
Drug: Fluocinonide 0.1%
Normalized name: FLUOCINONIDE 0.1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.1% cream
Study: 19663113
Drug: Clobetasol 0.05%
Normalized name: CLOBETASOL 0.05% EMOLLIENT TOP CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol 0.05% cream
Study: 19663113
Drug: Halobetasol 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol 0.05% cream
Study: 11245352
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose IVIG treatment
Study: 11245352
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MG treatment
Study: 11245352
Drug: No IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IVIG treatment (Control group)
Study: 8181191
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ketoconazole orally once daily for 4 days
Study: 8181191
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole orally once daily for 4 days
Study: 8181191
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo orally once daily for 4 days
Study: 8181191
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg midazolam administered on day 4
Study: 3371079
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg 3-times daily)
Study: 3371079
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg single daily dose)
Study: 30565543
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for dehydration, electrolyte disturbances, urinary tract infections, contusions, and bone fractures
Study: 26525521
Drug: Ticagrelor (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (initial dose of 180 mg and maintenance dose of 90 mg twice daily, n = 149)
Study: 26525521
Drug: Clopidogrel (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (initial dose of 300 mg and maintenance dose of 75 mg once daily, n = 151)
Study: 23877306
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam 0.25 mg/kg
Study: 23877306
Drug: Sublingual dexmedetomidine
Normalized name: dexmedetomidine Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dexmedetomidine 1.5 µg/kg
Study: 22275399
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg HA 2009 H1N1 vaccine
Study: 22275399
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg HA 2009 H1N1 vaccine
Study: 20737140
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate (2.5 mg daily, 20 mg intermittent)
Study: 20737140
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (0.5 mg, 1 mg quarterly)
Study: 18276620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NT-proBNP and E/Ea
Study: 26376805
Drug: Imipramine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (200-300 mg)
Study: 10093625
Drug: Epirubicin (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (at doses equivalent to doxorubicin)
Study: 10093625
Drug: Epirubicin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (higher doses)
Study: 8063233
Drug: CA 125
Normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 125 (> 65 U/ml)
Study: 8063233
Drug: CA 125
Normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 125 (> 35 U/ml)
Study: 8063233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of US and CA 125 (> 65 U/ml)
Study: 2899510
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg b.d.
Study: 2899510
Drug: Indenolol 60
Normalized name: Indenolol
DrugBank: Indenolol (DB08952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenolol 60 mg o.d.
Study: 2899510
Drug: Tyramine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine (i.v. boluses of 1-6 mg)
Study: 20932669
Drug: Early radiotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early radiotherapy (RT) with chemotherapy (fluorouracil 375 mg/m(2)/day and leucovorin 20 mg/m(2)/day) starting on Day 1 of the first chemotherapy cycle
Study: 20932669
Drug: Late radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late radiotherapy (RT) with chemotherapy (fluorouracil 375 mg/m(2)/day and leucovorin 20 mg/m(2)/day) starting on Day 1 of the third chemotherapy cycle
Study: 15311098
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (increased use of antihypertensive medications)
Study: 18046883
Drug: Calcium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel blockers (CCBs)
Study: 15311098
Drug: Overall BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall BP awareness and treatment
Study: 9661022
Drug: ZDV (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV (200 mg every 8 h) alone for 4 days
Study: 9661022
Drug: Ritonavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (300 mg q6h) alone for 4 days
Study: 8151265
Drug: Metformin, 850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 850 mg b.i.d.
Study: 8151265
Drug: Metoprolol CR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR, 100 mg o.d.
Study: 2575021
Drug: Beta adrenergic‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta adrenergic‐blocking agents administered in the acute phase of myocardial infarction
Study: 26208230
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of tranexamic acid (TXA) 15 mg/kg
Study: 24179982
Drug: Immediate Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Group (immediate implant placement and provisionalisation)
Study: 24179982
Drug: Delayed Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Group (immediate socket grafting followed by implant placement and provisionalisation after 4 months)
Study: 19567910
Drug: Amoxicillin 40
Normalized name: amoxicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 40 mg/kg/day in three doses
Study: 16546635
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics (Group Ab: 2.4 mIU of intramuscular penicillin G benzathine or 5-7 day regimen of oral clindamycin if allergic)
Study: 16546635
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics (Group non-Ab)
Study: 10662479
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B plus G-CSF (1 mg/kg daily plus 3 to 5 micrograms/kg daily)
Study: 10662479
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B monotherapy (1 mg/kg daily)
Study: 10662479
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B plus G-CSF
Study: 10662479
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B monotherapy
Study: 26319283
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioural therapy (delivered once a week for 10 weeks)
Study: 26319283
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioural therapy
Study: 9359660
Drug: Hydroxyurea and
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea and didanosine (ddI) combination treatment
Study: 7946687
Drug: Ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate 320 mg I/ml
Study: 9990415
Drug: Tretinoin 0.05%
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.05% cream
Study: 9748886
Drug: Piracetam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (12 g i.v. bolus) with Dextran 40 (500 ml daily)
Study: 9748886
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Dextran 40 (500 ml daily)
Study: 7827714
Drug: Lidocaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (200 to 250 mg loading and 3 mg/min maintenance infusions)
Study: 7827714
Drug: Procainamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (1 gm loading and 3 to 4 mg/min maintenance infusions)
Study: 22752958
Drug: Modified-release prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release prednisone (5 mg)
Study: 22752958
Drug: Standard prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prednisolone (5 mg)
Study: 28969890
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri strain DSM 17938 (5 × 10^8 colony-forming units daily)
Study: 26159012
Drug: Danlong Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlong Oral Liquid (DOL), 10 mL each time, 3 times per day for 7 days
Study: 26159012
Drug: Kechuanning Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kechuanning Oral Liquid (KOL), 10 mL each time, 3 times per day for 7 days
Study: 21982673
Drug: Oral informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral informed consent
Study: 21982673
Drug: All formats
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formats (oral, written, video)
Study: 19356104
Drug: Nevirapine/Efavirenz treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine/Efavirenz treatment (follow-up patients)
Study: 17069471
Drug: RS‐86 (M1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS‐86 (M1 mAChR agonist)
Study: 9397080
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg twice daily
Study: 6340971
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg twice daily
Study: 8635369
Drug: Triazolam, 0.25
Normalized name: Triazolam, 0.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam, 0.25 mg
Study: 3742936
Drug: Flurazepam (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam (dose not specified)
Study: 29669442
Drug: Targeted Interdisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME)
Study: 24983776
Drug: Ovarian artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian artery velocimetry in women needing HCG administration
Study: 20730517
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=19)
Study: 10534247
Drug: 10,000 U
Normalized name: Erwinaze 10,000 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 U BoNT/B (NeuroBloc) administered in a single session into two to four clinically involved muscles.
Study: 6578788
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment with comprehensive support and a 24-hour crisis service
Study: 29941991
Drug: IP6 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP6 supplements for 3 months
Study: 26211605
Drug: Ergocalciferol (vitamin
Normalized name: ergocalciferol (vitamin D2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol (vitamin D2) 50,000 IU twice weekly for 8 weeks
Study: 26211605
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 50,000 IU weekly for 8 weeks
Study: 17268068
Drug: FK506 (Tacrolimus);
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 (Tacrolimus); dosage and duration not specified
Study: 17268068
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MG(FK-)); no FK506 administration
Study: 17268068
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Healthy subjects); no FK506 administration
Study: 16119511
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefepime 4 g/d
Study: 16119511
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of cefepime 2 x 2 g
Study: 9385488
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg QD
Study: 9385488
Drug: lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 15 mg QD
Study: 9385488
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg QD
Study: 9385488
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg QID
Study: 8187316
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (Group 1)
Study: 8187316
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times daily (Group 2)
Study: 8187316
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg three times daily (Group 3)
Study: 3108170
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (900-1,200 mg/day for 4 days)
Study: 30395486
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy)
Study: 30395486
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atomoxetine
Study: 30395486
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxybutynin
Study: 21293249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of losartan and mizoribine (n = 34)
Study: 12664518
Drug: Tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2 mg/kg
Study: 16717306
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg/kg
Study: 14687095
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 micro g.kg‐1
Study: 14687095
Drug: Remifentanil 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2.0 micro g.kg‐1
Study: 14687095
Drug: Remifentanil 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3.0 micro g.kg‐1
Study: 14687095
Drug: Control (Propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Propofol and Mivacurium 0.2 mg.kg‐1)
Study: 14687095
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 micro g.kg‐1 and Control
Study: 11352853
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg once daily for 28 days
Study: 9205820
Drug: Draflazine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draflazine 0.25 mg
Study: 9205820
Drug: Draflazine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draflazine 0.5 mg
Study: 7650223
Drug: Draflazine 1
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Draflazine 1 mg
Study: 9205820
Drug: Draflazine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draflazine 1.5 mg
Study: 9205820
Drug: Draflazine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draflazine 2.5 mg
Study: 9205820
Drug: Draflazine 1
Normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Draflazine 1 mg followed by 1 mg h‐1 infusion
Study: 8025138
Drug: Myocardial revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial revascularization (surgical therapy)
Study: 29562405
Drug: Penehyclidine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine hydrochloride 0.05 mg/kg
Study: 27600995
Drug: gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine + erlotinib (G + E)
Study: 27600995
Drug: gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine + placebo (G + P)
Study: 25302067
Drug: Tianjiu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianjiu therapy for 1 year
Study: 25302067
Drug: Tianjiu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianjiu therapy for 2 years
Study: 31881232
Drug: Egg oral
Normalized name: Egg Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg oral immunotherapy (OIT)
Study: 12691271
Drug: Braun Oral-B
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral-B 3D Excel (D17)
Study: 9820263
Drug: Yoga-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-based intervention consisting of 11 yoga postures, given twice weekly for 8 weeks
Study: 9820263
Drug: Wrist splint
Normalized name: Wrist Splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist splint to supplement current treatment
Study: 8562352
Drug: Four-drug chemotherapy
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug chemotherapy regimen (ECMV: etoposide, cyclophosphamide, methotrexate, vincristine)
Study: 8562352
Drug: Two-drug chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug chemotherapy regimen (EV: etoposide and vincristine)
Study: 8562352
Drug: Four-drug chemotherapy
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug chemotherapy regimen (ECMV)
Study: 8562352
Drug: Two-drug chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug chemotherapy regimen (EV)
Study: 2012514
Drug: Controlled-release Sinemet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release Sinemet (levodopa/carbidopa)
Study: 30616671
Drug: Regional adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional adipose tissue grafting (AT-G)
Study: 14634808
Drug: Action effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action effects with target-compatible color effects (e.g., blue word -> left key -> blue patch)
Study: 1662562
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg once daily
Study: 2758453
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg diltiazem